Brought to you by 
Shire buys Premacure AB
26 Aug 2020
Executive Summary
Expanding its rare disease drug pipeline, Shire PLC has acquired closely held Swedish neonatology biotech Premacure AB for an undisclosed up-front payment and earn-outs based on development and commercialization of its Phase II protein replacement therapy for retinopathy of prematurity (ROP).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire buys Premacure AB
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice